The overall immunogenicity and prognostic relevance of immune markers in dMMR/MSI-H CRC depend on tumor stage, and immune profiling could be used for early-stage patient stratification and also suggests the potential benefit of early immunotherapeutic intervention.
Abstract
ABSTRACT Early-stage colorectal cancer (CRC) with confirmed microsatellite instability generally has a favorable prognosis associated with pronounced immune infiltration. However, some patients still develop metastases. The underlying mechanisms, particularly those related to the tumor immune microenvironment, remain incompletely understood. The study included tissue samples from 217 patients with dMMR/MSI-H CRC, comprising 89 stage III/IV and 128 stage I/II cases. Tissue microarrays and immunohistochemical analyzes were performed for all cases. We evaluated immune markers identifying T cells, B cells, dendritic cells, natural killer cells, macrophages, immunosuppressive markers, and immune checkpoint targets in epithelial and stromal compartments, and additionally performed a cohort-derived immune infiltration score (IIS). The survival analysis assessed the prognostic impact of immune markers stratified by tumor stage. Stage I/II dMMR/MSI-H CRCs showed significantly higher CD3⁺ T-cell and natural killer cell levels, higher IIS metrics across all regions, and higher CD4⁺ T helper cell levels in the stroma. Stage III/IV cases exhibited increased epithelial expression of indoleamine 2,3-dioxygenase 1. Given the limited number of stage IV patients, an additional stage III vs. stage I/II comparison was performed, revealing that these immune differences were already evident at the level of nodal progression. In addition, CD3⁺, CD4⁺, and CD8⁺ T cells and the IIS showed varying prognostic associations across tumor stages. These findings suggest that the overall immunogenicity and prognostic relevance of immune markers in dMMR/MSI-H CRC depend on tumor stage. Immune profiling could be used for early-stage patient stratification and also suggests the potential benefit of early immunotherapeutic intervention.
T-cell abundance and immune effectiveness can be uncoupled in MSS CRC, and a molecular case report shows that T-cell abundance and immune effectiveness can be uncoupled in MSS CRC.
Wen-Xu Liu, Yi Zheng, Hao Wang et al.· Cancer Genomics & Proteomics· 0 citations
HGSOC ascites showed a Treg-enriched immune profile, with relatively higher Treg levels in BRCA-wild-type cases, while BRCA-wild-type status was associated with poorer outcomes, while the evaluated immune-cell subsets were not independently prognostic in exploratory analysis.
Megha Sharma, Bhavneet Kaur, B. Rai et al.· Journal of Pathology and Tra...· 0 citations
Systemic immune remodeling is identified as a characteristic of advanced endometrial cancer and the potential of circulating immune profiling for patient stratification and prognostic assessment is supported, pending validation in larger prospective cohorts.
Raquel Piñeiro-Pérez, Ana Vilar, E. Arias et al.· bioRxiv· 0 citations
A tissue residency gene program in Tex cells associated with non-response to immunotherapy was identified and nominates resident memory exhausted CD8+ T cells as a targetable subset of cells to improve CD8+ T cell-mediated anti-tumor immunity.
Rishabh Rout, S. Kashima, M. Hugaboom et al.· The Oncologist· 0 citations
An exploratory, integrative analysis using single-cell RNA sequencing of TNBC patients operationally stratified into Good and Bad Prognosis groups suggests a framework in which tumor-intrinsic DNA damage signaling is associated with MHC-I antigen presentation upregulation and CD8 cytotoxic T-cell engagement, supporting...
Zinab O. Doha, E. AbuAzzah, Hakeemah H Al-Nakhle· Current Issues in Molecular...· 0 citations
High CD103⁺ tumor-infiltrating lymphocyte infiltration may be associated with improved overall survival in bladder cancer, particularly in muscle-invasive bladder cancer patients undergoing surgery with adjuvant chemotherapy.
Eduardo Germano Teixeira, L. A. Torres, Maria L. R. Defante et al.· Urologic oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.